The development of innovative drug industry accelerates, Hang Seng Biotechnology ETF Guotai (520930) surges over 2% intraday, industry trends and catalysts attract attention.

The innovation drug industry is accelerating, and on April 7, the Cathay Hang Seng Biotechnology ETF (520930) saw intraday gains of more than 2%, with industry trends and catalysts in focus.

China Merchants Securities noted that China’s domestic innovation drug industry is developing in a practical and rapid way, with overseas expansion continuously accelerating: from January to March this year, the total value of China’s innovation drug out-licensing exceeded 60 billion, nearing half of 2025; since 2026 to date, 10 innovative drugs have been approved (8 domestic), achieving historic breakthroughs. Recently, Hong Kong-listed pharmaceutical companies disclosed annual reports; overall performance in the Pharma+Biotech segment has been largely realized. BD and overseas revenue sharing are being reflected in company statements in stages, supporting a cycle of innovation for high-quality companies. In addition, major academic conferences such as AACR and ASCO are coming up from April to June, and multiple innovative drug companies are expected to release major data in succession—catalysts are worth watching. With adjusted healthcare sector liquidity not being crowded, it is believed that in Q2, healthcare’s attention across the entire market and allocation opportunities are likely to improve.

The Hang Seng Biotechnology Index focuses on innovation drugs’ “crown jewels,” with three advantages: leading companies concentrated × scarce futures liquidity × high upside potential & high Sharpe ratio. If investors want a convenient way to participate in the core innovation drug leaders, they can consider the Cathay Hang Seng Biotechnology ETF (520933) to achieve a one-click allocation.

Risk warning: Mentioning individual stocks is only for industry event analysis and does not constitute any recommendation or investment advice for any individual stock. Short-term gains and losses in indexes are for reference only and do not represent their future performance, nor do they constitute any promise or guarantee regarding fund performance. Views may be adjusted as market conditions change and do not constitute investment advice or commitments. The risk-reward characteristics of the mentioned funds differ; investors are kindly reminded to carefully read the fund’s legal documents, fully understand product elements, risk ratings, and the principles of profit distribution, choose products that match their own risk tolerance, and invest prudently. For details on fund fees, please refer to the legal documents.

Daily Economic News